In Europe, use of selexipag together with strong inhibitors of the liver enzyme [[CYP2C8]], such as [[gemfibrozil]], is contraindicated because it increases concentrations of selexipag twofold, and its active metabolite 11-fold, potentially leading to more adverse effects.<ref>{{citation|title=Information des Bundesamtes für Sicherheit im Gesundheitswesen zu Uptravi|publisher=Österreichisches Bundesamt für Sicherheit im Gesundheitswesen|language=de|date=2017-06-07}}</ref>
